Clinical-stage biopharmaceutical company focused on developing small molecule therapies for cancer and autoimmune diseases.
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to advancing novel precision cancer medicines for underserved patient populations. Currently, the company's pipeline includes PRT543 and PRT811, both in Phase 1 clinical trials. PRT543 is being evaluated for select solid tumors and myeloid malignancies, while PRT811 targets solid tumors, including glioblastoma multiforme. These compounds exemplify Prelude's commitment to developing therapies that address significant unmet needs in oncology. In addition to its clinical programs, Prelude Therapeutics is actively progressing several preclinical candidates. Among them are PRT1419, a potent inhibitor of anti-apoptotic proteins, and PRT2527, a highly selective inhibitor of CDK9 with significant kinome selectivity. Furthermore, PRT-SCA2 is in preclinical stages, focusing on multiple genomically selected cancers, while PRT3645 represents a brain-penetrant molecule targeting CDK4/6. The company's robust preclinical pipeline underscores its strategic approach to developing diverse and innovative treatment options for cancer patients. Founded in 2016 and headquartered in Wilmington, Delaware, Prelude Therapeutics has rapidly emerged as a leader in precision oncology. By leveraging cutting-edge research and development capabilities, the company aims to transform the treatment landscape for cancer. With a strong emphasis on precision medicine and targeted therapies, Prelude Therapeutics continues to expand its portfolio of potential breakthrough treatments aimed at improving outcomes for cancer patients worldwide.